ArticleJournal of ovarian research2025
Long-read sequencing analysis of non-classical congenital adrenal hyperplasia prevalence and carrier frequency in Chinese polycystic ovarian syndrome patients.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SomeJournal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAdrenocortical hyperplasia is an autosomal recessive disorder characterized by congenital metabolic dysfunction, resulting in endocrine disturbances and abnormal sexual development (such as female masculinity), requiring lifelong hormonal therapy. Notably, non-classical congenital adrenal hyperplasia (NCCAH) exhibits clinical manifestations resembling polycystic ovary syndrome (PCOS), yet their therapeutic approaches in fertility treatment differ substantially. Importantly, NCCAH carries the risk of delivering offspring with severe adrenal hyperplasia, which presents far graver consequences than PCOS. Accurate differentiation between these two conditions is therefore crucial for proper clinical management. However, to date, no large-scale screening studies have been conducted to investigate the prevalence and carrier status of NCCAH among PCOS populations.
methodsA total of 1,372 suspected PCOS patients were genotyped by long-read sequencing in this study. To further clarify phenotypic characteristics, detailed clinical evaluation and laboratory analysis were conducted on 947 of these patients.
resultsThe prevalence of NCCAH in suspected PCOS patients was 0.73‰ (95% CIs: 0.02-4.05‰; 1/1,372). The carrier rate for the CAH variants in PCOS patients was 4.45% (61/1,371, 95% CIs: 3.42-5.68%), of which 78.69% were CYP21A2 variants. The carrier frequencies for classic CAH and NCCAH in PCOS patients were 1.46% (95% CIs: 0.89-2.24%) and 2.04% (95% CIs: 1.36-2.94%), respectively. PCOS patients with hirsutism exhibited a significantly higher NCCAH carrier rate compared to those without hirsutism (3.90% vs. 0.37%, p<0.001). However, other clinical features such as irregular menstrual cycles, insulin resistance, and obesity showed no correlation with CAH carrier status. No significant differences in clinical or paraclinical characteristics were found among CAH carriers.
conclusionsPCOS patients had similar CAH carrier rates with the general population in China, and carriers of CAH variants are generally asymptomatic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.